Santa Monica, CA (PRWEB) July 29, 2014 Professionals Treatment at Promises welcomes SallyAnn Cross, LCSW, as its executive director. In this role, Ms. Cross will oversee the addiction treatment program for professionals as well as collate systems and processes and streamline quality assurance and utilization management. Ms. Cross holds two masters degrees, one in multicultural counseling from Buffalo State University, and a masters of social work from California State University, Long Beach. She is also a licensed clinical social worker. Her areas of expertise include relapse prevention, harm reduction and cognitive behavioral therapy. She has worked with diverse populations, including, but not limited to, individuals with substance use disorders and co-occurring disorders, HIV and AIDS, battered women and children, autism spectrum disorders, and severely emotionally disturbed adolescents. We are very excited to have SallyAnns expertise on our Promises team, said Nanci Stockwell, LCSW, MBA, Promises regional vice president for California. SallyAnn has almost 30 years of experience in the field of social work including more than 20 in management. She has a lot of enthusiasm for the treatment of chemical dependency and her wisdom in the field makes her a perfect fit for our professionals program. Professionals Treatment at Promises … Continue reading →

A DNA molecule strand with human genome code. Photograph: Steven Hunt/Getty Images The unravelling of the human genetic blueprint has delivered a revolution in the study of health and disease. It is having an impact on treatments today and this will carry forward well into the coming century, a Nobel Prize winner has said. Prof Aaron Ciechanover was speaking yesterday on the margins of a research conference under way at the Trinity Biomedical Sciences Institute in Dublin. He won a shared Nobel Prize in chemistry in 2004 for his study of how the body breaks down and disposes of unwanted proteins. We are part of a revolution that will change the whole world of medicine, he said. New methods that grew out of molecular biology now help scientists discover the underlying genetic causes of disease and then identify drugs that might help in treatments. And it will help deliver drugs with fewer side effects, he said. But we are also entering a period when privacy will be a thing of the past, when your genetic blueprint will reveal things hidden in the genome, he said. It will also separate sex from reproduction given access to advanced technologies. It is going … Continue reading →

PUBLIC RELEASE DATE: 28-Jul-2014 Contact: Gina DiGravio gina.digravio@bmc.org 617-638-8480 Boston University Medical Center (Boston)-- Researchers from Boston University School of Medicine (BUSM) report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead to new drug treatment options that target PLXNA4 specifically. These findings appear in the Annals of Neurology. AD is the most frequent age-related dementia affecting 5.4 million Americans including 13 percent of people age 65 and older, and more than 40 percent of people age 85 and older. Genetic factors account for much of the risk for developing AD with heritability estimates between 60 percent and 80 percent. However much of the genetic basis for the disease is unexplained. Less than 50 percent of the genetic contribution to AD is supported by known common genetic variations. Using data from the Framingham Heart Study, the researchers obtained strong evidence of an association with several single nucleotide polymorphism in PLXNA4, a gene which had not been previously linked to AD. They then confirmed this finding in a larger dataset from the Alzheimer's Disease Genetics Consortium and other datasets. Next, they performed a series of … Continue reading →

Irvine, CA and Annapolis Junction, MD (PRWEB) July 28, 2014 Proove Biosciences, the commercial and research leader in personalized medicine, will be exhibiting data and research conducted through their latest proprietary testing services at this years International Spine Intervention Societys (ISIS) 22nd Annual Scientific Meeting. The event will take place July 30th-August 3rd, at the Hyatt Regency, in Orlando, Florida. The meeting is designed to enhance the knowledge and clinical competence of physicians who care for patients suffering specificity from spine pain. The premier event will focus on the latest evidence-based findings, current research, and the future of the field. The International Spine Intervention Society is an industry leading organization dedicated to promoting the latest and most effective options for the treatment of pain from spine injury and disease, stated Proove Biosciences CEO, Brian Meshkin. Proove Biosciences has been recognized as a leader in personalized pain medicine and genetic testing, and uses evidence-based research to help physicians and patients better understand and treat their pain. Major components of this years forum will be emerging and alternative technologies in interventional spine care; how to prepare your practice in using outcome-based medicine and registries; and multiple research presentations. We are looking forward … Continue reading →

What is Okyanos Cardiac Stem Cell Therapy? Cardiac stem cell therapy is a promising new treatment option for advanced heart disease patients. This short video explores the procedure and benefits of adult stem cell therapy for severe... By: Okyanos Heart Institute … Continue reading →